Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure

Expert Review of Cardiovascular Therapy

Volumn 13, Issue 6, 2015, Pages 627-636

  Black Maier, Eric ^a   Steinberg, Benjamin A ^a   Piccini, Jonathan P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

atrial fibrillation; b blockers; bucindolol; genotype; heart failure

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BUCINDOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROPANOLAMINE DERIVATIVE;

ARTICLE; ATRIAL FIBRILLATION; AUTONOMIC NERVOUS SYSTEM; DRUG EFFECT; DRUG MECHANISM; GENETIC POLYMORPHISM; GENOTYPE; HEART FAILURE; HUMAN; PATHOPHYSIOLOGY; PHARMACOGENETICS; SINUS RHYTHM; COMPLICATION; GENETICS;

ADRENERGIC BETA-ANTAGONISTS; ATRIAL FIBRILLATION; HEART FAILURE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA-1;

EID: 84929907791     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2015.1031111     Document Type: Article

References (89)

1. Kelly PJ. Preventing the rise of AF-stroke in populations: a call to action. Circulation 2014;130(15):122
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) Study. J Am Med Assoc 2001;285:2370-5
3. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. Jama 1994;271:840-4
4. Gami AS, Hodge DO, Herges RM, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007;49:565-71
5. Heeringa J, Kors JA, Hofman A, et al. Cigarette smoking and risk of atrial fibrillation: the Rotterdam Study. Am Heart J 2008;156:1163-9
6. Larsson SC, Drca N, Wolk A. Alcohol consumption and risk of atrial fibrillation: a prospective study and dose-response meta-analysis. J Am Coll Cardiol 2014;64: 281-9
7. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331:1249-52
8. Go AS, Mozaffarian D, Roger VL, et al. Heart Disease and Stroke Statistics- 2013 Update: a Report From the American Heart Association. Circulation 2013;127: e6-e245
9. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920-5
10. Dorian P, Jung W, Newman D, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol 2000;36:1303-9
11. Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med 2008;168:418-24
12. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the american college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol 2013;62:e147-239
13. Mcalister FA, Ezekowitz JA, Wiebe N, et al. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med 2004;141:381-90
14. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91
15. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35
16. Dries D, Exner D, Gersh B, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998;32: 695-703
17. Chen P-S, Chen LS, Fishbein MC, et al. Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. Circ Res 2014;114:1500-15
18. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005;111: 2837-49
19. Bristow MR. Treatment of chronic heart failure with beta-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res 2011;109:1176-94
20. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation 1996;94:2285-96
21. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25
22. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55
23. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-9
24. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13
25. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 1997;30:1039-45
26. Rienstra M, Damman K, Mulder BA, et al. Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. JACC Heart Failure 2013;1:21-8
27. Wakili R, Voigt N, Kaab S, et al. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest 2011;121: 2955-68
28. Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA. Atrial Fibrillation Begets Atrial Fibrillation: a Study in Awake Chronically Instrumented Goats. Circulation 1995;92: 1954-68
29. Satoh T, Zipes DP. Unequal atrial stretch in dogs increases dispersion of refractoriness conducive to developing atrial fibrillation. J Cardiovasc Electrophysiol 1996;7:833-42
30. Morris JJ Jr, Entman M, North WC, et al. The changes in cardiac output with reversion of atrial fibrillation to sinus rhythm. Circulation 1965;31:670-8
31. Gwathmey JK, Copelas L, Mackinnon R, et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 1987;61: 70-6
32. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). The Lancet 1999;353:2001-7
33. Tate CW 3rd, Robertson AD, Zolty R, et al. Quality of life and prognosis in heart failure: results of the beta-blocker evaluation of survival trial (BEST). J Card Fail 2007;13:732-7
34. Foody J, Farrell MH, Krumholz HM. b-blocker therapy in heart failure: scientific review. J Am Med Assoc 2002;287:883-9
35. Hernandez AF, Hammill BG, Oconnor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (organized program to initiate lifesaving treatment in hospitalized patients with heart Failure) Registry. J Am Coll Cardiol 2009;53: 184-92
36. Wyse DG, Waldo AL, Dimarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33
37. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) Study. Circulation 2004;109:1509-13
38. Roy D, Talajic M, Nattel S, et al. Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure. N Engl J Med 2008;358:2667-77
39. Nergardh AK, Rosenqvist M, Nordlander R, Frick M. Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebo-controlled study. Eur Heart J 2007;28:1351-7
40. Nasr IA, Bouzamondo A, Hulot JS, et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 2007;28: 457-62
41. Arsenault KA, Yusuf AM, Crystal E, et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev 2013;1:CD003611
42. Deitchman D, Perhach JL Jr, Snyder RW. Beta-adrenoceptor and cardiovascular effects of MJ 13105 (bucindolol) in anesthetized dogs and rats. Eur J Pharmacol 1980;61: 263-77
43. Kreighbaum WE, Matier WL, Dennis RD, et al. Antihypertensive indole derivatives of phenoxypropanolamines with beta-adrenergic receptor antagonist and vasodilating activity. J Med Chem 1980;23: 285-9
44. Bristow MR. b-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-69
45. Hershberger RE, Wynn JR, Sundberg L, Bristow MR. Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharmacol 1990;15:959-67
46. Willette RN, Aiyar N, Yue TL, et al. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. J Pharmacol Exp Ther 1999;289:48-53
47. Bristow MR, Oconnell JB, Gilbert EM, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation 1994;89:1632-42
48. Bristow MR, Roden RL, Lowes BD, et al. The role of third-generation beta-blocking agents in chronic heart failure. Clin Cardiol 1998;21:I3-13
49. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 2006;103: 11288-93
50. Bristow MR, Krause-Steinrauf H, Nuzzo R, et al. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation 2004;110:1437-42
51. Bristow MR, Murphy GA, Krause-Steinrauf H, et al. An a2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the b-blocker bucindolol in chronic heart failure. Circ Heart Fail 2010;3:21-8
52. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23
53. Oconnor CM, Fiuzat M, Carson PE, et al. Combinatorial pharmacogenetic interactions of bucindolol and beta1, alpha2C adrenergic receptor polymorphisms. PLoS One 2012;7: e44324
54. Eichhorn EJ, Bedotto JB, Malloy CR, et al. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 1990;82:473-83
55. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23
56. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107: 1278-83
57. Bristow MR, Abraham WT, Yoshikawa T, et al. Second- and third-generation betablocking drugs in chronic heart failure. Cardiovasc Drugs Ther 1997(11 Suppl 1): 291-6
58. Small KM, Forbes SL, Rahman FF, et al. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 2000;275:23059-64
59. Small KM, Wagoner LE, Levin AM, et al. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002;347:1135-42
60. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 1999;274:12670-4
61. Taira CA, Monczor F, Hocht C. Measurement of inverse agonism in beta-adrenoceptors. Methods Enzymol 2010;485:37-60
62. Gilbert EM, Anderson JL, Deitchman D, et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990;88:223-9
63. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342:1441-6
64. Woodley SL, Gilbert EM, Anderson JL, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-41
65. Design of the Beta-Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee. Am J Cardiol 1995;75:1220-3
66. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67
67. Oconnor CM, Gottlieb S, Bourque JM, et al. Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. Am J Cardiol 2005;95: 558-64
68. Aleong RG, Sauer WH, Davis G, Bristow MR. New-onset atrial fibrillation predicts heart failure progression. Am J Med 2014;127:963-71
69. Eichhorn EJ, Mcghie AL, Bedotto JB, et al. Effects of bucindolol on neurohormonal activation in congestive heart failure. Am J Cardiol 1991;67:67-73
70. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-55
71. Kotecha D, Holmes J, Krum H, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014;384(9961):2235-43
72. Kao DP, Davis G, Aleong R, et al. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail 2013;15: 324-33
73. White HL, De Boer RA, Maqbool A, et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 2003;5:463-8
74. Sehnert AJ, Daniels SE, Elashoff M, et al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol 2008;52: 644-51
75. Aleong RG, Sauer WH, Sauer WH, et al. Prevention of atrial fibrillation by bucindolol is dependent on the beta(1) 389 Arg/Gly adrenergic receptor polymorphism. JACC Heart Failure 2013;1: 338-44
76. Jeff JM, Donahue BS, Brown-Gentry K, et al. Genetic variation in the beta1-adrenergic receptor is associated with the risk of atrial fibrillation after cardiac surgery. Am Heart J 2014;167:101-8
77. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human b1-adrenergic receptor. J Biol Chem 1999;274:12670-4
78. Genetically targeted therapy for the prevention of symptomatic atrial fibrillation in patients with heart failure (GENETICAF). Available from: www.clinicaltrials.gov/ct2/show/NCT01970501
79. Maury M, Berdeaux A, Kher A, et al. Comparative beta-adrenoceptor blocking effect and pharmacokinetics of bucindolol and propranolol in man. Eur J Clin Pharmacol 1985;27:649-56
80. Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet 1994;26:335-46
81. Oconnor PC, Finch MJ, Harron DW, et al. Comparison of the haemodynamic effects of bucindolol, propranolol and pindolol in healthy volunteers. Br J Clin Pharmacol 1985;20:659-67
82. Meredith PA, Kelman AW, Mcsharry DR, et al. The pharmacokinetics of bucindolol and its major metabolite in essential hypertension. Xenobiotica 1985;15:979-85
83. Oosterhuis B, Jonkman JHG, Kerkhof FA. Pharmacokinetic and pharmacodynamic comparison of a new controlled-release formulation of metoprolol with a traditional slow-release formulation. Eur J Clin Pharmacol 1988;33:S15-18
84. Ripley TL, Saseen JJ. b-Blockers: A Review of Their Pharmacological and Physiological Diversity in Hypertension. Ann Pharmacother 2014;48:723-33
85. Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol 2007;120:10-27
86. Pedersen ME, Cockcroft JR. The latest generation of beta-blockers: new pharmacologic properties. Curr Hypertens Rep 2006;8:279-86
87. Metra MA, Bristow MB. Beta-blocker therapy in chronic heart failure. W.B Saunders; Philadelphia: 2010
88. Pollock SG, Lystash J, Tedesco C, et al. Usefulness of bucindolol in congestive heart failure. Am J Cardiol 1990;66:603-7
89. Heesch CM, Marcoux L, Hatfield B, Eichhorn EJ. Hemodynamic and energetic comparison of bucindolol and metoprolol for the treatment of congestive heart failure. Am J Cardiol 1995;75:360-4